IDEXX Stocks Surge to $640M Volume Amid Strategic Expansion Boosting 286th Market Activity Rank

On September 19, 2025, , . The stock’s performance followed a strategic focus on expanding its veterinary diagnostics and digital solutions, as highlighted in recent corporate updates. Analysts noted that the surge in volume reflects renewed institutional interest in the company’s long-term growth prospects, particularly in its companion animal health segment.

Recent developments underscore IDEXX’s commitment to innovation, with the company announcing a partnership to enhance its cloud-based veterinary data platform. This move aligns with broader industry trends toward in pet healthcare, positioning IDEXX to capture market share in a rapidly evolving sector. While no direct earnings or revenue figures were disclosed in the latest reports, the strategic direction has drawn positive attention from investors seeking exposure to high-margin technology-driven healthcare services.

To ensure we structure the back-test exactly the way you intend, could you please clarify a couple of details? 1. Market universe: Do you want to screen all U.S.–listed common stocks (NYSE + NASDAQ) or a different universe (e.g., only S&P 500 constituents, all A-shares, etc.)? 2. Trade convention: The typical implementation is “buy at today’s close, sell at tomorrow’s close.” Is that acceptable, or would you prefer open-to-open or another convention? 3. Weighting: Should each of the 500 names be equally weighted each day (i.e., 1/500 of equity per name), or would you like volume-weighting or another scheme? 4. Transaction costs / slippage: Should we assume zero costs, or apply a default cost model (e.g., 2 bps per side) to make the results more realistic? Once we have these points confirmed, I can set up the data-gathering plan and run the back-test for you.